Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Focused Acceptance and Commitment Therapy With Workplace Involvement for Employees on Sick Leave

11 de noviembre de 2026 actualizado por: University of Aarhus

Effectiveness of Focused Acceptance and Commitment Therapy With Workplace Involvement for Employees on Sick Leave Due to Common Mental Disorders: A Randomized Controlled Trial

The investigators aim to evaluate the effectiveness of Focused Acceptance and Commitment Therapy combined with workplace involvement (FACT-WI) in reducing perceived stress, improving psychological well-being, and supporting return to work among employees on sick leave due to common mental disorders.

Descripción general del estudio

Descripción detallada

In the present study, participants will be randomly assigned to one of two groups, receiving either Focused Acceptance and Commitment Therapy with Workplace Involvement (FACT-WI) or treatment as usual (TAU). FACT-WI will be delivered flexibly according to individual needs over a three-month period, with the possibility of involving the participant's immediate manager to support return to work.

  1. It is hypothesized that FACT-WI will be more effective than TAU in reducing perceived stress and improving quality of life over time.
  2. It is hypothesized that participants receiving FACT-WI will return to work more quickly than participants receiving TAU, including both part-time and full-time return to work.
  3. The feasibility and acceptability of FACT-WI will be evaluated.
  4. The number and duration of sessions received, as well as the extent and format of workplace involvement, will be explored.
  5. Managers' experiences of workplace involvement, including its perceived relevance, usefulness, barriers, facilitating factors, and suggestions for improvement, will be explored.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

70

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Vita Ligaya Ponce Dalgaard, PhD, MSc
  • Número de teléfono: 004587165805
  • Correo electrónico: ligayadalgaard@psy.au.dk

Copia de seguridad de contactos de estudio

  • Nombre: Astrid Olesen Liboriussen, MSc
  • Número de teléfono: 004553356030
  • Correo electrónico: astridol@psy.au.dk

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Inclusion criteria are (i) age ≥ 18 years, (ii) currently being on part-time or full-time sick leave at the start of the study, (iii) symptoms of anxiety measured with the Generalized Anxiety Disorders (GAD ≥ 9) questionnaire and/or symptoms of depression assessed with the Patient Health Questionnaire (PHQ-9 ≥ 10) and/or symptoms of stress measured with the Perceived Stress Scale (PSS-10 ≥ 17), (iv) Danish language proficiency, (v) ability and willingness to give informed consent, (vi) access to either a smartphone, tablet, or computer with video camera. (vii) Be currently employed and anticipate to continue employment within the organizational setting. (viii)) have been employed in the current organization for a minimum of six months.

Exclusion Criteria:

Exclusion criteria are: (i) currently receiving other psychotherapy for the same problem, (iii) a history of bipolar disorder, (ii) current or past psychotic disorder, (iv) substance abuse or dependence judged to require treatment, (v) suicide risk requiring immediate hospitalization. (vi) being on sick leave for more than 4 months at the time of inclusion. (vii) a somatic or medical condition that is considered to prevent the participant from RTW. (viii) PTSD symptoms that re-quire treatment beyond the scope of the brief intervention. (ix) having an active Section 56 agreement under the Danish Sickness Benefits Act at the time of inclusion. In addition, potential participants must be clinically assessed as suitable for this brief intervention.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: FACT-WI

Brief ACT-based intervention with optional workplace involvement

Focused Acceptance and Commitment Therapy with Workplace Involvement (FACT-WI) is a brief, flexible intervention based on Acceptance and Commitment Therapy (ACT). The intervention aims to increase psychological flexibility, reduce psychological distress, and support return to work.

Participants receive up to 300 minutes of online therapist contact over a period of three months. The intervention is tailored to individual needs and focuses on identifying psychological and work-related barriers, promoting values-based action, and developing strategies to support return to work.

Workplace involvement is offered when relevant and may include written communication with the participant's immediate manager, verbal contact, or a joint meeting between the participant, manager, and therapist. The purpose is to address work-related barriers and facilitate a sustainable return to work. Workplace involvement is voluntary and requires the participant's consent.

Otro: Treatment as Usal (TAU)

Treatment as usual (TAU), including any support or services ordinarily available to employees on sick leave.

Participants allocated to the control group will receive treatment as usual (TAU). They will have access to the usual healthcare and support services available to employees on sick leave, including relevant services provided by the municipality, workplace, or healthcare system.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Perceived stress
Periodo de tiempo: Change from baseline to 3 months (post-treatment) and 6 months (follow-up).

Perceived Stress Scale-10 (PSS-10; Cohen & Williamson, 1988). The scale consists of 10 items rated from 0 to 4, resulting in a total score ranging from 0 to 40. Higher scores indicate higher levels of perceived stress (i.e., a negative outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up).
Quality of life (well-being)
Periodo de tiempo: Change from baseline to 3 months (post-treatment) and 6 months (follow-up).

the World Health Organization-5 questionnaire (Bech, 1999; Topp et al., 2015; WHO-5). 5 items are rated on a scale from 0 to 5 with total scores ranging from 0 to 25. Higher scores are indicative of higher levels of life quality (i.e., a positive outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up).

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Time to Return to Work (RTW)
Periodo de tiempo: From baseline to 3 months (post-treatment) and 6 months (follow-up).

Time to return to work, including both part-time and full-time return to work. Using administrative sickness absence records.

From baseline to 3 months (post-treatment) and 6 months (follow-up).
Sickness Absence Percentage
Periodo de tiempo: At 3 months (post-treatment) and 6 months (follow-up).

Percentage of scheduled working time lost due to sickness absence, based on administrative sickness absence records. Higher percentages indicate greater sickness absence (i.e., a negative outcome).

At 3 months (post-treatment) and 6 months (follow-up).
Depressive symptoms
Periodo de tiempo: Change from baseline to 3 months (post-treatment) and 6 months (follow-up)

Patient Health Questionnaire-9 (Kroenke et al., 2001; Spitzer et al., 1999; Spitzer et al., 2000; PHQ-9). 9 items are rated on a scale from 0 to 3, with a potential total range from 0 to 27. Larger scores mean more depressive symptoms (i.e., a negative outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up)
Anxiety symptoms
Periodo de tiempo: Change from baseline to 3 months (post-treatment) and 6 months (follow-up)

General Anxiety Disorder-7 (Spitzer et al., 2006; GAD-7). 7 items are rated on scale from 0 to 7 with total scores ranging from 0 to 21. Higher scores are indicative of more symptoms of GAD (i.e., a negative outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up)
Valued Living
Periodo de tiempo: Change from baseline to 3 months (post-treatment) and 6 months (follow-up)

Valuing Questionnaire (Smout et al., 2014; VQ). 10 items are rated on a scale from 0 to 6 with total scores ranging from 0 to 60. Higher scores a indicative of actions/life being guided by personally held values (i.e., a positive outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up)
Harm/negative effects
Periodo de tiempo: Measured once at post-treatment (3 months), in the intervention group only.

The Negative Effects Questionnaire (Rozental et al., 2019; NEQ). 32 questions are answered yes/no. If yes, items are rated on a scale from 1 to 5 and participants are asked if the negative effect experience can be attrubuted to the treatment or other crcumstances. Total scores range from 32 to 160 with higher scores indicating more negative effects (i.e., a negative outcome).

Measured once at post-treatment (3 months), in the intervention group only.
Experiental Avoidance
Periodo de tiempo: Change from baseline to 3 months (post-treatment) and 6 months (follow-up).

Brief Experiential Avoidance Questionnaire (BEAQ; Gámez et al., 2014). The questionnaire consists of 15 items rated from 1 to 6, resulting in a total score ranging from 15 to 90. Higher scores indicate greater experiential avoidance (i.e., a negative outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up).
Client Satisfaction Questionnaire
Periodo de tiempo: Measured once at 3 months (follow-up), in the intervention group only.

Client Satisfaction Questionnaire-8 (CSQ-8; Larsen et al., 1979). The questionnaire consists of eight items rated from 1 to 4, resulting in a total score ranging from 8 to 32. Higher scores indicate greater satisfaction with the intervention. The questionnaire will be administered to participants in the FACT-WI group only.

Measured once at 3 months (follow-up), in the intervention group only.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

25 de enero de 2027

Finalización primaria (Estimado)

1 de agosto de 2028

Finalización del estudio (Estimado)

1 de agosto de 2028

Fechas de registro del estudio

Enviado por primera vez

11 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Publicado por primera vez (Actual)

19 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir